Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 102

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 102
---
 that we will be able to do so on a timely basis. The commercial success of our tests and our ability to generate revenues will depend on a variety of factors, including acceptance in the medical community, patient acceptance and demand, patient compliance with orders for our tests by healthcare providers, and patient adherence to recommendations regarding periodic re -testing, successful sales, marketing, and educational programs, including successful direct -to -consumermarketing such as television advertising and social media, the number of patients screened, the number of women diagnosed, the amount and nature of competition from other products and procedures, maintaining regulatory approvals to legally market, the ease of use of our ordering process for healthcare providers, maintaining and defending patent protection for the intellectual property relevant to our products and services, and our ability to establish and maintain adequate commercial, distribution, sales and laboratory testing capabilities. If we are unable to continue to grow sales of our tests in Argentina and abroad, are unable to build a business beyond Argentina or are delayed or limited in doing so, our business prospects, financial condition and results of operations would be adversely affected. Additionally, we are devoting significant resources to the development of our new products. The successful commercialization of these tests will also be subject to the factors listed above, among others. If we are unable to successfully commercialize these new products, our business, results of operations, financial condition and growth prospects may be adversely affected. We depend on CIBIC, one of our indirect shareholders, for a substantial part of our revenues, and if the Commercialization Agreement is terminated, our business and results of operations would be materially adversely affected. On January 3, 2017, Heritas Argentina entered into a commercialization agreement, as amended on October1, 2018 by addendum No.1, and on February1, 2025 by addendum No. 2 (the “Commercialization Agreement”) with CIBIC, a shareholder of the Parent, pursuant to which we appointed CIBIC as exclusive agent for the commercialization of Heritas Diagnostics tests in Argentina. Pursuant to the Commercialization Agreement, CIBIC supplies, according to the specifications and requirements of Heritas Argentina, the requisite reagents and equipment. Furthermore, 25 CIBIC is responsible for covering the maintenance expenses of the equipment necessary for the implementation of the Commercialization Agreement. In consideration thereof, we, through Heritas Argentina delivers the final report to execute the activities and services contemplated by the Commercialization Agreement. We are exposed to significant customer concentration risk as our